🇺🇸 FDA
Pipeline program

QVM149 150/50/160

CQVM149B2302

Phase 3 small_molecule completed

Quick answer

QVM149 150/50/160 for Asthma is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Asthma
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials